CA
Cresta Advisors, Ltd.
13F filer · CIK 0001947670Reported Jul 22, 2026
Net buyer this quarter
13F portfolio value$279MU.S. long equity reported on 13F
Positions272 new · 1 closed
Net flow last quarter+$5.09MBuys minus sells
Top 10 positions weight36.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 22, 202627 positions | |||||
| $42.4M | 15.21% | Not reported | +6.5% | Q1 2023 | |
| $14.3M | 5.15% | Not reported | +3.2% | Q3 2022 | |
| $9.75M | 3.50% | 0.00% | -0.7% | Q3 2022 | |
| PBPMBSPuramed Bioscience Inc. | $8.48M | 3.05% | 0.09% | +6.3% | Q3 2024 |
| $6.08M | 2.18% | 0.00% | +1.6% | Q2 2023 | |
| $5.35M | 1.92% | Not reported | +18.2% | Q4 2022 | |
| $4.32M | 1.55% | 0.09% | -2.9% | Q3 2022 | |
| $3.74M | 1.34% | 0.00% | +1.4% | Q3 2022 | |
| $3.51M | 1.26% | 0.00% | -20.8% | Q3 2022 | |
| $3.34M | 1.20% | Not reported | +31.3% | Q4 2025 | |
| $2.67M | 0.96% | Not reported | +0.1% | Q3 2022 | |
| $1.78M | 0.64% | 0.00% | +17.1% | Q3 2022 | |
| $1.67M | 0.60% | Not reported | Not reported | Q1 2023 | |
| $1.52M | 0.55% | 0.00% | -1.1% | Q1 2023 | |
| $982K | 0.35% | 0.00% | Not reported | Q3 2025 | |
| $882K | 0.32% | Not reported | Not reported | Q2 2023 | |
| $749K | 0.27% | Not reported | Not reported | Q3 2022 | |
| $747K | 0.27% | 0.00% | -20.0% | Q4 2023 | |
| $700K | 0.25% | 0.00% | Not reported | Q4 2025 | |
| $632K | 0.23% | 0.00% | Not reported | Q4 2023 | |
| $630K | 0.23% | 0.00% | Not reported | Q3 2022 | |
| $533K | 0.19% | 0.00% | Not reported | Q3 2022 | |
| $509K | 0.18% | 0.00% | Not reported | Q1 2023 | |
| $452K | 0.16% | Not reported | Not reported | Q3 2022 | |
| $449K | 0.16% | Not reported | Not reported | Q1 2023 | |
| $305K | 0.11% | 0.00% | Not reported | Q3 2022 | |
| $300K | 0.11% | Not reported | Not reported | Q3 2024 | |
| Q1 2026Reported Apr 27, 202626 positions | |||||
| $34.6M | 14.18% | Not reported | +7.5% | Q1 2023 | |
| $10.9M | 4.46% | Not reported | +1.6% | Q3 2022 | |
| $8.62M | 3.53% | 0.00% | -1.3% | Q3 2022 | |
| PBPMBSPuramed Bioscience Inc. | $8.02M | 3.28% | 0.08% | +2.1% | Q3 2024 |
| $5.22M | 2.14% | 0.00% | +2.6% | Q2 2023 | |
| $4.33M | 1.77% | Not reported | +43.0% | Q4 2022 | |
| $3.94M | 1.61% | 0.09% | Not reported | Q3 2022 | |
| $3.88M | 1.59% | 0.00% | +2.4% | Q3 2022 | |
| $2.97M | 1.22% | 0.00% | +15.0% | Q3 2022 | |
| $2.71M | 1.11% | Not reported | -3.9% | Q3 2022 | |
| $2.5M | 1.02% | Not reported | +410.7% | Q4 2025 | |
| $1.63M | 0.67% | Not reported | Not reported | Q1 2023 | |
| $1.57M | 0.64% | 0.00% | +1.5% | Q3 2022 | |
| $1.53M | 0.63% | 0.00% | +94.1% | Q1 2023 | |
| $1.15M | 0.47% | 0.00% | -2.9% | Q3 2025 | |
| $748K | 0.31% | 0.00% | Not reported | Q3 2022 | |
| $717K | 0.29% | Not reported | -4.7% | Q2 2023 | |
| $709K | 0.29% | 0.00% | Not reported | Q4 2023 | |
| $698K | 0.29% | 0.00% | +370.2% | Q4 2025 | |
| $611K | 0.25% | 0.00% | Not reported | Q3 2022 | |
| $603K | 0.25% | 0.00% | Not reported | Q1 2023 | |
| $488K | 0.20% | Not reported | +116.7% | Q3 2022 | |
| $485K | 0.20% | 0.00% | Not reported | Q4 2023 | |
| $446K | 0.18% | Not reported | Not reported | Q1 2023 | |
| $311K | 0.13% | 0.00% | Not reported | Q3 2022 | |
| $238K | 0.10% | 0.00% | New | Q1 2026 | |
| Q4 2025Reported Feb 3, 2026108 positions | |||||
| $33.8M | 14.17% | Not reported | +0.6% | Q1 2023 | |
| $11.4M | 4.78% | Not reported | -1.3% | Q3 2022 | |
| $9.35M | 3.92% | 0.00% | -0.3% | Q3 2022 | |
| PBPMBSPuramed Bioscience Inc. | $7.87M | 3.30% | 0.08% | +3.2% | Q3 2024 |
| $5.44M | 2.28% | 0.00% | -0.1% | Q2 2023 | |
| $4.2M | 1.76% | 0.00% | +8.2% | Q3 2022 | |
| $3.89M | 1.63% | 0.09% | -2.9% | Q3 2022 | |
| $3.26M | 1.37% | Not reported | -1.1% | Q3 2022 | |
| $3.14M | 1.31% | Not reported | +5.1% | Q4 2022 | |
| $2.81M | 1.18% | 0.00% | -19.2% | Q3 2022 | |
| $1.64M | 0.69% | Not reported | Not reported | Q1 2023 | |
| $1.31M | 0.55% | 0.00% | -1.5% | Q3 2022 | |
| $1.09M | 0.46% | 0.00% | Not reported | Q3 2025 | |
| $1.03M | 0.43% | 0.00% | +10.6% | Q1 2023 | |
| $894K | 0.38% | Not reported | +25.0% | Q2 2023 | |
| $599K | 0.25% | 0.00% | Not reported | Q3 2022 | |
| $568K | 0.24% | 0.00% | New | Q4 2025 | |
| $566K | 0.24% | 0.00% | -1.5% | Q4 2023 | |
| $564K | 0.24% | 0.00% | -7.5% | Q3 2022 | |
| $525K | 0.22% | 0.00% | Not reported | Q3 2025 | |
| $489K | 0.21% | 0.00% | Not reported | Q1 2023 | |
| $487K | 0.20% | Not reported | New | Q4 2025 | |
| $450K | 0.19% | Not reported | Not reported | Q1 2023 | |
| $329K | 0.14% | 0.00% | Not reported | Q3 2022 | |
| $293K | 0.12% | Not reported | Not reported | Q3 2024 | |
| $207K | 0.09% | Not reported | Not reported | Q3 2022 | |
| $151K | 0.06% | 0.00% | Not reported | Q3 2022 | |
| $146K | 0.06% | 0.00% | New | Q4 2025 | |
| $137K | 0.06% | 0.00% | New | Q4 2025 | |
| $132K | 0.06% | 0.00% | New | Q4 2025 | |
| $126K | 0.05% | Not reported | New | Q4 2025 | |
| $99.4K | 0.04% | 0.00% | New | Q4 2025 | |
| $91.4K | 0.04% | Not reported | New | Q4 2025 | |
| $86.4K | 0.04% | 0.00% | New | Q4 2025 | |
| $75.4K | 0.03% | 0.00% | New | Q4 2025 | |
| $72.2K | 0.03% | 0.00% | New | Q4 2025 | |
| $71.7K | 0.03% | 0.00% | New | Q4 2025 | |
| $70.1K | 0.03% | 0.00% | New | Q4 2025 | |
| $65.8K | 0.03% | 0.00% | New | Q4 2025 | |
| $64K | 0.03% | Not reported | New | Q4 2025 | |
| $57.6K | 0.02% | 0.00% | New | Q4 2025 | |
| PCPTYPimco Corporate & Income Opportunity Fund | $51.6K | 0.02% | Not reported | Not reported | Q1 2023 |
| $50.6K | 0.02% | 0.00% | New | Q4 2025 | |
| $50.5K | 0.02% | 0.00% | New | Q4 2025 | |
| $49.3K | 0.02% | Not reported | Not reported | Q3 2022 | |
| $48.3K | 0.02% | 0.00% | New | Q4 2025 | |
| $45.8K | 0.02% | 0.00% | New | Q4 2025 | |
| $44.5K | 0.02% | 0.00% | New | Q4 2025 | |
| $44K | 0.02% | 0.00% | New | Q4 2025 | |
| $43.9K | 0.02% | 0.00% | New | Q4 2025 | |
| Q3 2025Reported Oct 22, 202524 positions | |||||
| $32.8M | 14.65% | Not reported | +5.3% | Q1 2023 | |
| $11.3M | 5.04% | Not reported | -7.6% | Q3 2022 | |
| $8.78M | 3.92% | 0.00% | -7.2% | Q3 2022 | |
| PBPMBSPuramed Bioscience Inc. | $7.62M | 3.40% | 0.08% | +12.7% | Q3 2024 |
| $5.45M | 2.43% | 0.00% | +32.5% | Q2 2023 | |
| $4.15M | 1.85% | 0.10% | -2.0% | Q3 2022 | |
| $3.69M | 1.65% | 0.00% | +24.6% | Q3 2022 | |
| $3.67M | 1.64% | Not reported | Not reported | Q3 2022 | |
| $2.92M | 1.30% | Not reported | Not reported | Q4 2022 | |
| $2.7M | 1.21% | 0.00% | -8.3% | Q3 2022 | |
| $1.62M | 0.72% | Not reported | Not reported | Q1 2023 | |
| $1.3M | 0.58% | 0.00% | +1.7% | Q3 2022 | |
| $996K | 0.44% | 0.00% | Not reported | Q1 2023 | |
| $976K | 0.44% | 0.00% | New | Q3 2025 | |
| $739K | 0.33% | Not reported | Not reported | Q2 2023 | |
| $618K | 0.28% | 0.00% | Not reported | Q3 2022 | |
| $597K | 0.27% | 0.00% | Not reported | Q3 2022 | |
| $529K | 0.24% | 0.00% | New | Q3 2025 | |
| $528K | 0.24% | 0.00% | Not reported | Q1 2023 | |
| $462K | 0.21% | Not reported | Not reported | Q1 2023 | |
| $408K | 0.18% | 0.00% | Not reported | Q4 2023 | |
| $333K | 0.15% | 0.00% | Not reported | Q3 2022 | |
| $299K | 0.13% | Not reported | Not reported | Q3 2024 | |
| $202K | 0.09% | Not reported | Not reported | Q3 2022 | |
Premium opens every quarter this fund has filed